Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evommune (EVMN) Net Margin (2024 - 2025)

Evommune (EVMN) has disclosed Net Margin for 2 consecutive years, with 124.75% as the latest value for Q3 2025.

  • Quarterly Net Margin fell 9374828.0% to 124.75% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 775.22% through Dec 2025, changed N/A year-over-year, with the annual reading at 598.45% for FY2025, 35595.0% up from the prior year.
  • Net Margin for Q3 2025 was 124.75% at Evommune, down from 93623.53% in the prior quarter.
  • The five-year high for Net Margin was 93623.53% in Q3 2024, with the low at 124.75% in Q3 2025.